TPO and autoimmune thrombocytopenic purpura: Almost two-thirds of patients with chronic ITP received oral TPO compared to 33.3% and 0% in persistent and newly diagnosed ITP with highly significant difference (p < 0.05) while 66.7% of patients with newly diagnosed ITP and chronic ITP received corticosteroids as the first-line therapy versus 86.7% in patients with persistent ITP with no significant difference(p > 0.05).